BMRAHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 31 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Biomerica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BMRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2020 | Aegis Capital | Maintains | Buy | $13 → $11 |
| 4 Sept 2020 | Aegis Capital | Maintains | Buy | — |
| 21 Aug 2020 | Aegis Capital | Initiates | Buy | — |
| 17 Dec 2018 | B. Riley FBR | Maintains | Buy | — |
| 17 Dec 2018 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BMRA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Biomerica, Inc. returned −37.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 54% of US stocks
Cheaper than 40% of US stocks
Cheaper than 71% of US stocks
Higher than 17% of US stocks
Higher than 56% of US stocks
Higher than 3% of US stocks
Higher than 14% of US stocks
Higher than 5% of US stocks
Higher than 12% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biomerica, Inc. has a market value of $7.9M and an enterprise value of $7.5M.
Revenue in the twelve months to 31 May 2026: $4.5M. The latest quarter shrank 8.3% year on year.
Net income over the same four quarters: −$3.8M, a −84.8% net margin.
Free cash flow in the twelve months to 31 May 2026: −$3.4M.
Trailing P/E: −0.9×; forward P/E: 4.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Biomerica, Inc. employs 50 people — $89K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biomerica, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biomerica reported financial results for the first quarter of fiscal 2027, which ended August 31, 2026.
Why it matters — The announcement provides BMRA watchers with the company’s latest quarterly financial update, though the excerpt does not include the results themselves.
Biomerica, Inc. reported its financial results for the fiscal year ended May 31, 2026, in a news release dated September 1, 2026. The company disclosed the results via GlobeNewswire from its Irvine, California headquarters.
Why it matters — This announcement provides BMRA shareholders with the company's official year-end financial performance data, a key reporting event for monitoring the company's fiscal health.
Biomerica announced it entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of its common stock at $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the company.
Why it matters — BMRA watchers would care because the private placement provides additional capital to the company through the issuance of new shares.
Of the 1 analysts covering Biomerica, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biomerica, Inc. 14 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Biomerica, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No analyst covering Biomerica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRA are extrapolating price history, which says nothing about the business.
Biomerica, Inc. returned -37.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products.
The most recent item we track (GlobeNewsWire, 16 Oct 2026): "Biomerica Reports First Quarter Fiscal 2027 Financial Results". Biomerica reported financial results for the first quarter of fiscal 2027, which ended August 31, 2026.
Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products. The company’s portfolio centers on in-vitro diagnostic solutions used in point-of-care settings, physicians’ offices, and hospital and clinical laboratories. Its products address a range of medical conditions, with emphasis on gastrointestinal and inflammatory diseases, food intolerances, diabetes, and other diagnostic applications. Biomerica Inc. also serves clinical laboratory, physician office, home testing, and over-the-counter channels, supporting early detection and treatment decisions across multiple healthcare environments. Based in Irvine, California, the company operates as a specialized healthcare provider with a market presence in both diagnostic testing and therapeutic product development.
CEO Mr. Zackary S. Irani · 50 employees · United States · https://www.biomerica.com
